1 – 10 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial
2024) In European Urology(
- Contribution to journal › Article
- 2023
-
Mark
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality : 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
(
- Contribution to journal › Article
- 2022
-
Mark
PSA : role in screening and monitoring patients with prostate cancer
2022) p.131-172(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2019
-
Mark
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy : An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
-
Mark
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article
-
Mark
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men
(
- Contribution to journal › Article
-
Mark
Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL : results from the Göteborg randomized population-based prostate cancer screening trial
(
- Contribution to journal › Article
- 2017
-
Mark
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
(
- Contribution to journal › Article